Details of the Drug Reposition

General Information of This Drug (ID: DM53J6B)

Drug Name
PDR001   DM53J6B
Drug Type
Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Melanoma DIS1RRCY 2C30 Phase 3 [1]
------------------------------------------------------------------------------------
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Neuroendocrine cancer DISVGJET 2B72.1 Phase 2 [2]
Esophageal squamous cell carcinoma DIS5N2GV 2E60.1 Phase 2 [3]
------------------------------------------------------------------------------------
2 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1 [2]
Lymphoma DISN6V4S 2A80-2A86 Phase 1 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02967692) A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (COMBI-i). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT03785496) Study to Evaluate Efficacy of PDR001 in Patients With Squamous Cell Carcinoma of the Esophagus. U.S. National Institutes of Health.